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Sixty-four patients with symptomatie hereditary
hemorrhagie telangieetasia were retrospectively studied
in order to determine the true incidence of clinical
manifestations in this disease. This select group had a
significantly higher incidence of gastrointestinal hem-
orrhage and pulmonary arterovenous fistula formation
than has been previously reported. Data are presented
regarding the course and severity of nasal and gastroin-
testinal hemorrhage, the use of endoscopy for diagnosis,
the incidence of associated neurological, cardiac, and
hepatic disease, and mortality.
INTRODUCTION
Hereditary hemorrhagic telangiectasia (HHT) is an
autosomal dominant inherited disease (1) characterized
by telangiectasias ofthe skin, mucous membranes, and
various organ systems. Its clinical presentation is vari-
able as regards both number of vascular lesions and
severity of organ dysfunction secondary to these lesions.
Telangiectasias have been described on all body sur-
faces, but are most common about the head, the ex-
tremities, and the chest (2). They also occur in all parts
ofthe alimentary tract (3), as well as the lungs (4), brain
(2), retina (5), and liver (6, 7).
Previous studies attempting to define the clinical
manifestations of this disease included asymptomatic
relatives of index cases (2, 4), thereby underestimating
the incidence and severity of organ specific lesions. This
study was undertaken to define the manifestations of
HHT in a symptomatic patient population to establish
a more accurate estimate of the incidence and severity
of these findings. This is the subset of patients that the
clinician is likely to see.
METHODS
The records of all patients seen at the University of
Michigan affiliated hospitals and clinics (University
Hospital 1954-1980, Ann Arbor VA Hospital 1965-
1980, and Wayne County General Hospital 1970-1980)
with the diagnosis of HHT were reviewed. Sixty four
patients fulfilled the following requirements: 1) cuta-
neous and mucosal telangiectasias, 2) active HHT re-
lated disease at the time of presentation, and 3) a family
history and/or personal history of episodic undiagnosed
nasal or gastrointestinal hemorrhage.
RESULTS
Fifty-six percent of the patients were male and 44%
were female. There was no relationship of sex to severity
of illness or number of organ systems involved. The age
at diagnosis varied from 2 days to 85 years with a
median age of 44 years. Symptoms began at a median
of 20 years before diagnosis (range 0-78 years). A family
history compatible with the diagnosis of HHT was
recorded in 74%.
Clinical manifestations (incidence)
Table 1 lists the various clinical manifestations of
patients at inital presentation. The most common sign
was epistaxis with 78% of patients having this at some
time during their course, and 51% of patients having
this sign at initial presentation. Gastrointestinal (Gl)
bleeding was second in overall frequency at 44%, and
this was the initial sign in 25%. The remaining patients
had a' wide range of complaints related to skin and
pulmonary lesions as well as CNS disease. Three pa-
tients who presented with complaints unrelated to HHT
were found to have HHT-related disease.
TABLE 1
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Skin and mucosal lesions
Telangiectasias were found most commonly on the
hands and feet. The most frequent locations were the
palms and soles of the feet, tips of the digits, as well as
the subungual and periungual areas (Table 2). Although
mucosal telangiectasias were seen at one time or an-
other on the nasal mucosa of 78% of patients, these are
of little use diagnostically because of obscuration ofthe
nasal mucosa related to recurrent epistaxis. No corre-
lation between the location of skin or mucosal lesions
and GI hemorrhage was found.
Epislaxis
Epistaxis was not only the most common presenting
manifestation of HHT but also the most common
symptom overall (78%). We divided the group into
"minor" and "major" categories depending on the re-
quirement for transfusion (minor = no transfusions,
major = greater than or equal to one transfusion).
Slightly more than one-third of all patients with epis-
taxis had major hemorrhage (Table 3). More than one-
half developed epistaxis in the first decade of life (Fig.
1). The course of epistaxis was progressive in 54% and
static in 42%, the latter defmed as no change from the
previous pattern of bleeding or transfusion require-
ments. Four percent had spontaneous regression of
bleeding. Ten patients with major epistaxis were treated
with varying doses of estrogen, and ofthe these five had
no sustained response while five had significant reduc-
tion or cessation of epistaxis for follow-up periods of
2-10 years. All of the estrogen-treated patients had
significant unpleasant symptoms related to therapy,
primarily gynecomastia, and vaginal bleeding, but none
had any recognizable major complications. Fourteen
TABLE 2
HHT: Distribution of telangiectasias (64 Patients)
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FIG. 1. Epistaxis: age at onset.
patients with major epistaxis underwent a total of 20
septal dermoplasty procedures. Of the 11 patients fol-
lowed for 2-4 years, 60% had no beneficial effects while
25% had reduction or cessation of bleeding.
GI hemorrhage
GI hemorrhage was the second most common pre-
senting manifestation, and was present at some time in
28 of the 64 patients (44%). Using the same minor/
major classification scheme that was applied to epis-
taxis, a little more than half of the patients had major
GI hemorrhage, which represents 25% of the entire
series (Table 4). In contrast to epistaxis, the onset of GI
bleeding was usually in the fifth decade of life or later
(Fig. 2). To describe accurately the site of bleeding, the
following criteria were applied: 1) upper GI bleeding
was defined by hematemesis, a positive nasogastric
aspirate in the absence of epistaxis, or actively bleeding
lesions found at the time of upper GI endoscopy; 2)
lower GI bleeding was defined by hematochezia or
actively bleeding lesions at sigmoidoseopy; 3) if criteria
1 or 2 were not fulfilled, bleeding was considered in-
determinate, e.g., melena with a negative endoscopy or
endoscopic visualization of nonbleeding telangiectasias.
Eleven (40%) of 28 patients met the criteria for upper,
three (10%) for lower GI bleeding, and in 14 (50%) the
bleeding site was indeterminate. Eighteen of the 28
patients were followed for 2-6 years, and of these two-
thirds had continued chronic intermittent bleeding,
while one-third had steady progression in the degree of
hemorrhage. In contrast to epistaxis, none of the pa-
tients with GI hemorrhage underwent spontaneous
regression.
Esophagogastroduodenoscopy was performed on 17
patients and 12 (70%) had typical lesions in the stom-
ach, although none was actively bleeding at the time of
the examination (Table 5). No esophageal or duodenal
lesions were described. Nine percent of all patients and
14% of those with GI hemorrhage had coexisting duo-
denal ulcer disease. Sigmoidoseopy demonstrated telan-
giectasias in only four of the 23 patients studied and
barium x-rays were uniformly nonrevealing. Angiogra-
phy demonstrated multiple visceral telangiectasias in
two patients where prior evaluation including upper
endoscopy was unrewarding. Colonoscopy was per-
formed in one patient and showed an actively bleeding
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telangiectatic lesion that was successfully treated by
electrocautery.
Pulmonary lesions
Twenty percent of our patients had pulmonary arter-
ovenous fistulas (AVFs) and of these approximately
one-third had multiple lung lesions. All were demon-
strable on standard chest x-rays (and confirmed angio-
graphically) except in one case where multiple micro-
scopic AVFs were diagnosed at autopsy. Among nine
patients with solitary AVFs, one had resultant polycy-
themia and transient ischemic attacks; otherwise none
had symptoms or signs directly referable to their lung
lesions. In contrast, all three patients with multiple
macroscopic AV fistulas presented with major CNS
complications as shown in Table 6. Four of the five
patients with CNS complications had pulmonary
AVFs, while one patient with a brain abscess had no
evidence of pulmonary lesions cHnically or at postmor-
tem examination.
Liver disease
Liver disease was defined as the presence of hepato-
megaly and/or levels of serum transaminases or alkaline
phosphatase more than two times normal. Twenty pa-
tients (31%) fulfilled these criteria, and 10 of these
either underwent percutaneous liver biopsy or came to






* Included under brain abscess,
hepatic congestion and 30% had hepatic telangiectasias.
Iron overload (3+ or more) was seen in 50%. Periportal
fibrosis (eight patients), occasional serate hepatocellular
necrosis (three patients), or lobular fat deposition with-
out a significant history of alcohol intake (two patients)
were in 40% of patients. There was no patient with
fully developed cirrhosis, bridging necrosis, or chronic
active hepatitis. Combinations of these findings were
found in half of the patients studied.
Miscellaneous disease
Twenty percent had clinical evidence of right, left, or
biventricular cardiac failure without any explanation
other than HHT. The patients with pulmonary AVFs
were remarkably free of clinically apparent cardiac
disease, with high output states due to anemia and
systemic arteriovenous shunting accounting for almost
all cases of heart disease. No scintigraphic or cardiac
angiographic studies were performed. There was no
evidence of iron overload clinically or at the time of
autopsy.
Only one of the 64 patients had Von Willebrand's
disease and she was lost to follow-up at age 20, by which
time she had not sustained any life-threatening hem-
orrhage.
Eleven ofthe 64 patients died in one of our hospitals,
and of these, six died of unrelated causes at a median
age of 75 years, while five died of causes directly related
to HHT or its therapy at a median age of 46 years.
DISCUSSION
All prior studies of HHT have included families or
large groups containing varying numbers of asympto-
matic individuals. The data obtained from such studies,
although valid as stated, will necessarily underestimate
the frequency of the various components of the syn-
drome depending on the number of asymptomatic
persons included. When this number or fraction is not
given, the data presented cannot be interpreted in a
meaningful way. In addition, our diagnostic criteria
were chosen to separate HHT as accurately as possible
from the various other diseases with which it may be
confused (Table 7), something that has not been ad-
hered to strictly in prior studies.
The equal sex distribution and the high percentage
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of positive family histories in this study are in accord
with earlier estimates (2, 4). The distribution of skin
and mucosal lesions differed from that of Smith et al.
(2) in that we did not fmd a correlation between GI
bleeding and telangiectatic lesions of the lips. Despite
the absence of any specific prognostic significance, the
distribution of lesions is of importance in evaluating
epistaxis or GI bleeding of unknown etiology.
The incidence for many ofthe clinical manifestations
of this disease has not been previously described, al-
though the prominence of epistaxis and GI hemorrhage
is not unexpected. In the only other study ofthe inci-
dence of GI hemorrhage in HHT (2) only 13% of 159
patients bled from the GI tract. This is in striking
contrast to the 44% of 64 patients reported here, and is
likely due to the fact that the earlier study included an
unspecified number of asymptomatic family members.
The delay in onset of GI hemorrhage in contrast to
the early onset of epistaxis deserves further comment.
Since degenerative vascular telangiectasias are a com-
mon endoscopic finding in the elderly and may be a
source of significant GI bleeding (8, 9) perhaps such
degenerative changes have an additive effect on the
genetic defect in HHT, accounting for the relatively
late onset and high incidence of GI bleeding that we
observed. The early onset of epistaxis is explainable by
the location ofthe mucosal lesions and their accessibil-
ity to trauma (10).
Therapy for hemorrhage in HHT regardless of the
source has been disappointing. Transfusion and iron
supplementation remain the only well-accepted treat-
ments, with the possible exception of nasal dermoplasty
for epistaxis. This operation involves placing a skin
graft intranasally to protect the fragile telangiectatic
vessels from local trauma. Previous series have shown
this procedure to be useful, with success rates much
higher than we found (11, 12). Variable factors such as
patient selection and surgical skill enter into the deci-
sion to proceed with this operation. Medical therapy
for epistaxis in HHT has included the administration
of such varied substances as ascorbic acid, rutin, snake
venon, androgens, and estrogens. None has stood the
test of time with the possible exception of estrogen
therapy, which seems to be of some benefit in noncon-
trolled trials (11, 13). Its mechanism of action is be-
TABLE 7
Vascular Malformations Involving Skin and/or Mucous Membrance
HHT
Multiple phlebeclasia








lieved to be induction of squamous metaplasia of the
nasal mucosa, thereby providing a protective barrier for
the telangiectasias.
A review of the literature regarding GI bleeding in
HHT indicates that in select cases surgical resection
can be effective in treating isolated repeatedly bleeding
telangiectasias, at least in the short term (15, 16). These
operations have not met with lasting success due to
repeated episodes of bleeding from other mucosal le-
sions, but have been of use in the management of
uncontrollable life-threatening hemorrhage. Location
ofthe source of GI bleeding is crucial. Definition ofthe
source of bleeding could only be accomplished in 50%
of our patients by clinical means although telangiecta-
sias could be seen at the time of upper GI endoscopy
in 70%. The specific role of endoscopic therapy,
whether by electrocautery or laser photocoagulation, is
poorly defined. A major limiting factor is the difficulty
encountered in endoscopic visualization of actively
bleeding leisons. Although vascular lesions can be easily
visualized, therapy aimed at potential rather than actual
bleeding sources may be fruitless and possibly danger-
ous. Clinical bleeding localized to the upper GI tract
was only found in 40% of our patients. The use of
colonoscopy to localize potential colonic telangiectasias
and ''""Tc red blood cell scan to localize low grade
bleeding points may improve localization overall, but
the impact of this on therapy remains uncertain.
The incidence of pulmonary AVFs has been esti-
mated at 6-7% based on family studies (4, 17) of HHT
but this lesion was far more common (20%) in this
select population. Secondary CNS disease may be due
to a variety of mechanisms including hypoxemia,
polycythemia, and embolization. Separation of infected
thrombi from the wall of the AVF is thought to be
responsible for brain abscess formation. In this study,
solitary AVFs did not predispose to a high risk of CNS
disease, whereas multiple AVFs universally did. The
occurrence of a brain abscess without pulmonary AVFs
is interesting; the proposed mechanism is that oral flora
gained direct access to the intracranial venous system
through mucosal telangiectasias.
The pathological changes in the liver in HHT have
been described (6, 7, 18). The degree of hepatic dys-
function may be severe leading to portal hypertension
and portosystemic encephalopathy (19, 20). Patients
with HHT are at risk for developing liver disease in a
variety of ways: 1) peliosis hepatitis, hepatic adenoma,
or even hepatocellular carcinoma secondary to long-
term hormonal therapy; 2) acute hepatitis potentially
followed by chronic liver disease and cirrhosis second-
ary to multiple transfusions; 3) iron overload state
secondary to transfusions and/or chronic oral iron ther-
apy; 4) passive congestion secondary to high output
heart failure caused by chronic anemia and arteriove-
nous shunting; 5) direct involvement of the liver with
HHT, either in the form of macroscopic AVMs, isolated
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microscopic telangiectasias, or a unique form of fibrosis
(telangiectasia-associated hepatic fibrosis or "pseudocir-
rhosis"). Our results show that combinations of these
findings are not unusual, with hepatic iron overload
being the most common single entity observed (50%).
None of the patients studied had cirrhosis or a signifi-
cant degree of fibrosis, but isolated hepatic telangiecta-
sias were seen in 30%.
The potentially devastating combination of Von Wil-
lebrand's disease and HHT has been previously re-
ported (21) but it remains unclear if this is a true
association or simply the random occurrrence of two
rare diseases in the same patient.
The increased incidence of duodenal ulcer with HHT
described by Smith et al. (2) was observed among our
patients as well, with a 14% incidence of duodenal ulcer
in patients who bled from the GI tract and 9% overall.
These numbers indicate that patients with HHT have
a higher chance of developing duodenal ulcer than the
general population, but the pathophysiological link be-
tween the two disease processes remains to be estab-
lished.
CONCLUSION
Patients with HHT presenting for medical attention
have a much higher incidence of significant multiorgan
system disease than previously reported. Nasal bleeding
remains the most common source for morbidity, and
currently available therapy (either hormonal or sur-
gical) still results in variable degrees of success.
GI bleeding occurs in 44% of patients but the source
of bleeding has been difficult to define despite the use
of urgent upper GI endoscopy. The application of en-
doscopic therapy (electrocoagulation and laser photo-
coagulation) to visible lesions must be studied in a
controlled fashion to determine their use in this disease,
where localization of bleeding is difficult and supportive
therapy is the only effective form of management.
In addition to the overwhelming incidence of GI
hemorrhage in patients with symptomatic HHT, pul-
monary disease also appears to be more common than
previously described, and leads to a high incidence of
devastating CNS manifestations such as brain abscess
and cerebrovascular accident. Close attention to these
complications must be routinely given during initial
examination of the patient with HHT.
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